Retatrutide and Sleep: Apnea, Heart Rate and Insomnia

Retatrutide and sleep: what the apnea trials measured

Nov 11, 2026•4 min read

Full clinical and regulatory review pending.

TL;DR

In two phase 3 studies, retatrutide reduced breathing interruptions during sleep compared with placebo in adults with obstructive sleep apnea and overweight or obesity. A separate trial reported an increase in heart rate. These findings leave open whether retatrutide causes insomnia or whether switching to tirzepatide changes that symptom.

Key takeaways

The retatrutide sleep apnea studies compared the drug with placebo over 80 weeks.
The apnea-hypopnea index counts breathing events during sleep. It does not measure insomnia symptoms.
A 48-week phase 2 retatrutide trial reported a heart-rate increase but does not show that it caused sleep problems.
The FDA decision on tirzepatide covers a specific sleep apnea population. Separate placebo comparisons cannot rank the two drugs.

Correction, November 11, 2026. An earlier version described retatrutide as no worse than tirzepatide for sleep apnea and said researchers had measured only one sleep outcome. The trials used separate placebo groups, and the retatrutide conference report lists additional sleep apnea outcomes. This update separates those measures from insomnia.

What the retatrutide apnea studies found

In a 2026 conference abstract, the study authors reported results from two randomized phase 3 trials. The studies compared weekly subcutaneous retatrutide with placebo over 80 weeks in adults with moderate to severe obstructive sleep apnea and a body mass index of at least 27. TRIUMPH-1-OSA included 243 adults without type 2 diabetes; TRIUMPH-2-OSA included 448 adults with type 2 diabetes.

The apnea-hypopnea index (AHI) counts pauses or reductions in breathing per hour of sleep. The report found a larger reduction in AHI with retatrutide than with placebo in both studies. It also reported how many participants reached remission or mild apnea without daytime sleepiness. That measure concerns sleep apnea and its symptoms. It does not show whether the drug makes it harder to fall or stay asleep. The conference abstract was the source for these results.

What the heart-rate finding tells us

A separate 48-week randomized phase 2 study of 338 adults with obesity or overweight and a weight-related condition compared weekly subcutaneous retatrutide with placebo. Its authors reported heart-rate increases that varied by dose, peaked at week 24 and then declined. The report does not establish that the change in pulse causes restless sleep or insomnia. ^[1]

Can the studies tell us what happens after a switch?

The FDA based its sleep apnea approval for tirzepatide on two 52-week randomized studies in adults with obesity and moderate to severe obstructive sleep apnea. One study included people using positive airway pressure and the other included people unable or unwilling to use it. The agency reported a greater reduction in AHI with tirzepatide than with placebo. The US indication is for this sleep apnea population, with a reduced-calorie diet and increased physical activity.

The studies had separate placebo groups, different follow-up times and differences in who was enrolled. They cannot establish that one drug works better for apnea or that switching would improve insomnia. To answer the switching question, a study would need to follow comparable patients and measure sleep symptoms and heart rate directly in both groups.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified clinician for individual medical decisions.

References

Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.. The New England journal of medicine, 2023.

Frequently asked questions

Does retatrutide cause insomnia?

The sources reviewed here do not establish whether retatrutide causes insomnia or how often it might occur. A reduction in breathing interruptions in a sleep apnea trial cannot answer that question.

What did the retatrutide sleep apnea trials measure?

They measured the change in the apnea-hypopnea index over 80 weeks in adults with moderate to severe obstructive sleep apnea and overweight or obesity. The index counts pauses or reductions in breathing per hour of sleep.

Does retatrutide raise heart rate?

A randomized phase 2 obesity study reported increases in heart rate that varied by dose, peaked around week 24 and then declined. The report does not establish that a faster pulse caused trouble sleeping.

Is tirzepatide better than retatrutide for sleep apnea or insomnia?

The studies discussed here compared each drug with placebo and cannot rank them. The US FDA approved tirzepatide for moderate to severe obstructive sleep apnea in adults with obesity, with diet and physical activity. That approval does not cover insomnia.